# Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

> **NCT02675530** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 33 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ketamine

## Key facts

- **NCT ID:** NCT02675530
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675530, "Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02675530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*